Substituted tetrahydroisoquinoline derivatives as D1 positive allosteric modulators

Abstract

The present invention relates to compounds according to formula (I), [Formula 1] JPEG2023553671000018.jpg3547 It is a positive allosteric modulator of D1 and is therefore useful as a pharmaceutical agent for the treatment of diseases involving the D1 receptor.

Description

[Technical Field]

[0001] The present invention relates to tetrahydroisoquinoline derivatives and their use in therapy. In particular, the present invention relates to pharmacologically active substituted tetrahydroisoquinoline derivatives.

[0002] This compound acts as a D1 positive allosteric modulator and is therefore useful as a pharmaceutical agent for the treatment of diseases involving the D1 receptor. [Background technology]

[0003] The monoamine dopamine acts through two families of GPCRs to regulate motor function, reward mechanisms, cognitive processes, and other physiological functions. Specifically, dopamine acts on neurons primarily through D1-like receptors, including dopamine D1 and D5, which are receptors that couple to Gs G proteins and thereby stimulate cAMP production, and D2-like receptors, including D2, D3, and D4, which are receptors that couple to Gi / q G proteins and attenuate cAMP production. These receptors are widely expressed in different brain regions. In particular, D1 receptors are involved in numerous physiological and behavioral processes. D1 receptors are involved in, for example, synaptic plasticity, cognitive function, and goal-directed motor function, as well as reward processes. Due to their involvement in physiological / neurological processes, D1 receptors have been implicated in a variety of disorders, including cognitive and negative symptoms in schizophrenia, cognitive impairment associated with neuroleptic therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinsonism-related dementia, Huntington's disease, dementia with Lewy bodies, Alzheimer's disease, drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain.

[0004] It is well known that developing orally bioavailable small molecules targeting the D1 receptor is difficult. D1 agonists developed to date generally feature a catechol moiety, limiting their clinical use to invasive treatments. Achieving sufficient selectivity has also been challenging due to the high degree of homology in the ligand-binding sites between dopamine receptor subtypes (e.g., dopamine D1 and D5). Furthermore, D1 agonists are associated with potentially limiting side effects, including, but not limited to, dyskinesia and hypotension.

[0005] Therefore, there is a need to design new drugs that can modulate D1 receptors. Identifying allosteric modulators of GPCRs has attracted considerable interest, both as tools for understanding receptor mechanisms and as potential therapeutic agents. GPCRs represent the largest family of cell surface receptors, and numerous marketed drugs directly activate or block signaling pathways mediated by these receptors. However, for some GPCRs (e.g., peptide receptors), the high degree of homology in the ligand-binding sites between subtypes (e.g., dopamine D1 and D5 or D2 and D3) has proven difficult to develop small molecules or achieve sufficient selectivity. Therefore, much drug research has shifted to identifying small molecules that target sites distinct from those of the orthosteric natural agonists.

[0006] Ligands that bind to these sites induce conformational changes in GPCRs, thereby allosterically modulating receptor function. Allosteric ligands possess a diverse range of activities, including the ability to enhance (positive allosteric modulators, PAMs) or attenuate (negative allosteric modulators, NAMs) the effects of endogenous ligands by affecting affinity and / or efficacy. As well as subtype selectivity, allosteric modulators may exhibit other potential advantages from a drug discovery perspective, such as a lack of direct effect or intrinsic efficacy, only enhancing the effect of the natural transmitter if and when released, a reduced tendency to induce desensitization resulting from constant exposure to agonists, and a reduced tendency to induce target-related side effects. Summary of the Invention

[0007] The compounds according to the invention potentiate the effects of D1 agonists or endogenous ligands on the D1 receptor via an allosteric mechanism and are therefore D1 positive allosteric modulators (D1 PAMs). The compounds according to the invention, which are D1 PAMs, are useful for the treatment and / or prevention of diseases and disorders in which the D1 receptor is involved, including cognitive and negative symptoms in schizophrenia, cognitive impairment associated with neuroleptic therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinsonism-related dementia, Huntington's disease, dementia with Lewy bodies, Alzheimer's disease, drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain.

[0008] International Patent Application WO2014 / 193781A1 discloses certain 3,4-dihydroisoquinolin-2(1H)-yl derivatives useful for the treatment of cognitive impairment associated with Parkinson's disease or schizophrenia. International Patent Application WO2017 / 178377 discloses certain substituted 3,4-dihydroisoquinol-2(1H)-yl derivatives and analogues thereof useful as D1 positive allosteric modulators. International Patent Application No. PCT / EP2020 / 068183, published as WO2021 / 001288, discloses 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone.

[0009] Despite this, there remains a need to develop alternative and potent D1 positive allosteric modulators. According to the present invention, there is provided 2-(3,5-dichloro-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone of formula (I) [ka] or a pharmaceutically acceptable salt thereof.

[0010] The present invention also provides a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof for use in therapy. As noted above, certain D1 PAM compounds have been disclosed in the prior art, however, the exact structures of the compounds have not previously been disclosed. In another aspect, the present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above for use in the treatment of diseases and / or disorders in which the D1 receptor is involved.

[0011] In another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above for use in the treatment and / or prophylaxis of cognitive and negative symptoms in schizophrenia, cognitive impairment associated with neuroleptic therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinsonism-related dementia, Huntington's disease, dementia with Lewy bodies, Alzheimer's disease, drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain. In a particular embodiment of this aspect, the invention provides a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof for use in the treatment of cognitive and negative symptoms in Parkinson's disease and other movement disorders, Alzheimer's disease, or schizophrenia.

[0012] Thus, in one particular aspect, the present invention provides a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of Parkinson's disease and other movement disorders. In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above for the manufacture of a medicament useful for the treatment and / or prevention of diseases and / or disorders in which the D1 receptor is involved.

[0013] In another further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above for the manufacture of a medicament useful for the treatment and / or prophylaxis of cognitive and negative symptoms in schizophrenia, cognitive impairment associated with neuroleptic therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinsonism-related dementia, Huntington's disease, dementia with Lewy bodies, Alzheimer's disease, drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain.

[0014] In a particular embodiment of this aspect, the invention provides the use of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for the treatment of cognitive and negative symptoms in Parkinson's disease and other movement disorders, Alzheimer's disease, or schizophrenia. In one particular aspect, the present invention provides the use of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful in the treatment of Parkinson's disease and other movement disorders.

[0015] The present invention also provides a method for the treatment and / or prevention of disorders for which administration of a D1 positive allosteric modulator is indicated, which method comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof.

[0016] In another aspect, the present invention provides a method for the treatment and / or prophylaxis of cognitive and negative symptoms in schizophrenia, cognitive impairment associated with neuroleptic therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinsonism-related dementia, Huntington's disease, dementia with Lewy bodies, Alzheimer's disease, drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain, which method comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof. In a particular embodiment of this aspect, the invention provides a method for the treatment of cognitive and negative symptoms in Parkinson's disease and other movement disorders, Alzheimer's disease, or schizophrenia, which method comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof.

[0017] In one particular aspect, the present invention provides a method for the treatment of Parkinson's disease and other movement disorders, which method comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof.

[0018] When used in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. However, other salts may also be useful in the preparation of compounds of formula (I) or their pharmaceutically acceptable salts. Standard principles underlying the selection and preparation of pharmaceutically acceptable salts are described, for example, in Handbook of Pharmaceutical Salts: Properties, Selection and Use, ed. P.H. Stahl & C.G. Wermuth, Wiley-VCH, 2002. Suitable pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts, which may be formed, for example, by mixing a solution of the compound of formula (I) with a solution of a pharmaceutically acceptable acid.

[0019] It is to be understood that the atoms of formula (I) or individual atoms present in the formulae shown below may in fact be present in any of their naturally occurring isotopic forms, with the most abundant isotopes being preferred. Thus, for example, an individual hydrogen atom present in formula (I) or the formulae shown below may be: 1 H, 2 H (deuterium) or 3 H (tritium) atoms, preferably 1 H. Similarly, for example, individual carbon atoms present in formula (I) or the formulae shown below may be present as: 12 C. 13 C or 14 C atoms, preferably 12 It may exist as C.

[0020] The present invention includes within its scope solvates of the compounds of formula (I) above. Such solvates may be formed using common organic solvents or water. The present invention also includes within its scope co-crystals of compounds of formula (I) above. The term "co-crystal" is used to describe a situation in which neutral molecular components exist in a crystalline compound in a defined stoichiometric ratio. The preparation of pharmaceutical co-crystals allows modifications to be made to the crystalline form of a pharmaceutically active ingredient, thereby altering its physicochemical properties without impairing its intended biological activity (see Pharmaceutical Salts and Co-crystals, ed. J. Wouters & L. Quere, RSC Publishing, 2012).

[0021] Compounds according to the present invention may exist in different polymorphic forms, and although not explicitly indicated in the above formula, such forms are intended to be included within the scope of the invention. In a particular embodiment according to the present invention, the compound of formula (I) is isolated in the form of a monohydrate, as further described in the examples. The present invention also includes within its scope prodrug forms of the compounds of formula (I) and the various sub-scopes and sub-groups of the same.

[0022] Of course, activity in any of the above therapeutic indications or disorders can be determined by conducting appropriate clinical trials in a manner known to those skilled in the art for the particular indication and / or in the design of clinical trials in general. To treat a disease, the compounds of formula (I) or their pharmaceutically acceptable salts may be administered in the form of a pharmaceutical composition at an effective daily dosage.

[0023] Therefore, the present invention also provides a pharmaceutical composition comprising a compound of formula (I) above or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers.

[0024] In preparing pharmaceutical compositions according to the present invention, one or more of the compounds of formula (I) or pharmaceutically acceptable salts thereof are intimately admixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical compounding techniques known to those skilled in the art. Suitable diluents and carriers can take a wide variety of forms and can depend on the intended route of administration, for example oral, rectal, parenteral, or intranasal.

[0025] Pharmaceutical compositions according to the invention may, for example, be administered orally, parenterally, ie intravenously, intramuscularly or subcutaneously, intrathecally, by inhalation or intranasally. Pharmaceutical compositions suitable for oral administration may be solid or liquid and may be in the form of, for example, tablets, pills, dragees, gelatin capsules, solutions, syrups, chewing gum, or the like.

[0026] For this purpose, the active ingredient may be mixed with an inert diluent or a non-toxic pharmaceutically acceptable carrier, such as starch or lactose. Optionally, these pharmaceutical compositions may also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatin, a disintegrating agent such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetener such as sucrose or saccharin, or a coloring agent or a flavoring agent such as peppermint or methyl salicylate.

[0027] The present invention also contemplates compositions that can release the active substance in a controlled manner. Pharmaceutical compositions that can be used for parenteral administration are in conventional forms such as aqueous or oily solutions or suspensions, which are generally contained in ampoules, disposable syringes, glass or plastic vials or infusion containers.

[0028] In addition to the active ingredient, these solutions or suspensions may optionally contain a sterile diluent such as water for injection, saline solution, oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulfite, chelating agents such as ethylenediaminetetraacetic acid, buffers such as acetates, citrates or phosphates, and agents for adjusting osmotic pressure such as sodium chloride or dextrose. These pharmaceutical forms are prepared using methods routinely used by pharmacists.

[0029] The amount of the compound used in the present invention required to prevent or treat a particular condition will vary depending on the compound selected and the condition of the patient being treated, but in general, daily dosages may range from 0.05 to 3000 mg, typically 0.5 mg to 1000 mg for parenteral compositions.

[0030] The compound according to the present invention or a pharmaceutically acceptable salt thereof may be administered alone (monotherapy) or in combination with L-dopa (combination therapy). Alone or in combination with a portion of the L-dopa dose required to improve a patient's motor dysfunction, the compound of formula (I) according to the present invention or a pharmaceutically acceptable salt thereof may be useful for treating dyskinesias associated with the administration of L-dopa. For example, when the compound of formula (I) according to the present invention is used together with a portion of the L-dopa dose given to a patient or used alone to replace L-dopa, the compound of formula (I) according to the present invention is believed to be effective against motor dysfunction without inducing troublesome dyskinesias. Therefore, it is believed that the compound according to the present invention may be useful for treating movement disorders and levodopa-induced dyskinesia (LID).

[0031] Thus, in one particular aspect, the present invention also provides compounds of formula (I) that are useful for the treatment of levodopa-induced dyskinesia (LID). Compounds of formula (I) may be prepared by a two-step process involving reaction of an intermediate of formula (II) with an intermediate of formula (III) followed by a deprotection step, where P1 and P2 are protecting groups such as tert-butyldimethylsilyl and trimethylsilyl, respectively. [ka]

[0032] Intermediate (III) may be conveniently first reacted with an intermediate of formula (II) in a suitable solvent such as dimethylformamide with an excess of a base such as N,N-diisopropylethylamine in the presence of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) or another coupling agent known to those skilled in the art. The resulting intermediate may be directly deprotected using a fluoride-based reagent such as tetrabutylammonium fluoride (TBAF) in THF or according to any method known to those skilled in the art.

[0033] The intermediate of formula (III) may be prepared by a process comprising reaction of an intermediate of formula (IV). [ka] In the above formula, Z represents halogen or 1-hydroxy-1-methylethyl; R a represents tert-butyldimethylsilyl; and R c represents hydrogen or tert-butoxycarbonyl.

[0034] In a first step, an intermediate of formula (IV), wherein Z represents bromo and R c represents hydrogen, hereinafter referred to as intermediate (IVa), may be protected with a suitable protecting group according to methods known to those skilled in the art to give a compound of formula (IV), wherein Z represents bromo and R c represents tert-butoxycarbonyl, hereinafter referred to as intermediate (IVb).

[0035] In the second step, a metal-halogen exchange reaction may be carried out, for example, in a suitable solvent such as tetrahydrofuran in the presence of n-BuLi at low temperature in continuous flow in the presence of dry acetone, according to the method described in the accompanying examples, to give the corresponding intermediate (IV) above, where Z represents 1-hydroxy-1-methylethyl, hereinafter referred to as intermediate (IVc).

[0036] Then, a tert-butoxycarbonyl (Boc) group (R c ) may first be deprotected according to methods known to those skilled in the art or as further described in the accompanying examples to provide intermediate (III).

[0037] The intermediate of formula (IVa) may be prepared by a process comprising reaction of an intermediate of formula (V): Y is halogen, for example bromo, and R a is defined above for the intermediate of formula (IV). [ka] The reaction may be carried out in a suitable solvent such as tetrahydrofuran in the presence of methylmagnesium chloride at low temperature.

[0038] The intermediate of formula (V) may be prepared by a two-step process involving reaction of an intermediate of formula (VI). [ka] wherein Y is as defined above for the intermediate of formula (V), and R a represents hydrogen or tert-butyl-dimethylsilyl.

[0039] In the first step, intermediate (VI) (wherein R a represents hydrogen) is reacted with tert-butyldimethylsilyl chloride in the presence of a suitable base, such as 4-dimethylamino-pyridine, at room temperature to give intermediate (VI). a represents tert-butyl-dimethylsilyl.

[0040] In a second step, intermediate (VI) is reacted with N-chlorosuccinimide (NCS) in a suitable solvent, such as THF, to give intermediate (V). a represents tert-butyl-dimethylsilyl.

[0041] As intermediate (VI), R a represents hydrogen may be prepared by a process which includes as an intermediate of formula (VII) wherein Y is as defined above for intermediate (V). [ka] The reaction is conveniently carried out in a suitable solvent, for example a mixture of ethanol and water, in the presence of a strong base, for example sodium hydroxide, at elevated temperature.

[0042] Intermediates of formula (VII) may be prepared by a process comprising reaction of intermediate (VIII). [ka] wherein Y is as defined herein above for the intermediate of formula (V). The reaction is carried out without problems in a suitable solvent, such as dichloromethane, in the presence of trimethylsilyl triflate and paraformaldehyde.

[0043] Intermediate (VIII) may be prepared by a two-step process involving the commercially available intermediate (IX). [ka] wherein Y is as defined above for intermediate (V). The reaction is carried out without difficulty according to the methods described in the accompanying examples or according to methods known to those skilled in the art. The intermediate of formula (II) may be prepared by chlorination of the intermediate of formula (X). [ka]

[0044] The reaction is conveniently carried out using a chlorinating agent such as N-chlorosuccinimide in a polar solvent mixture such as DMF at room temperature or according to any method known to those skilled in the art.

[0045] When a mixture of products is obtained from any of the above-described processes for the preparation of compounds according to the invention, the desired product may be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC or column chromatography utilizing, for example, silica and / or alumina in combination with a suitable solvent system.

[0046] If the above-described method for preparing the compound according to the present invention produces a mixture of stereoisomers, these isomers can be separated by conventional techniques. In particular, if it is desired to obtain a specific enantiomer of the compound of formula (I), it can be produced from the corresponding mixture of enantiomers using any suitable conventional procedure for separating enantiomers. Thus, for example, diastereomeric derivatives, such as salts, can be produced by reacting a mixture of an enantiomer of formula (I), such as a racemate, with a suitable chiral compound, such as a chiral base. The diastereomers can then be separated by any convenient means, for example, by crystallization, and the desired enantiomer can be recovered, for example, by treating with an acid if the diastereomer is a salt.

[0047] In another resolution method, the racemate of formula (I) may be separated using chiral HPLC. Furthermore, if desired, a specific enantiomer may be obtained by using an appropriate chiral intermediate in one of the above methods. Alternatively, a specific enantiomer may be obtained by enantiospecific enzymatic biotransformation, e.g., ester hydrolysis using an esterase, followed by purification of the enantiomerically pure hydrolyzed acid alone from the unreacted ester antipode. Chromatography, recrystallization, and other conventional separation procedures may be used with intermediates or final products if it is desired to obtain a specific geometric isomer of the present invention. Alternatively, the undesired enantiomer may be racemized to the desired enantiomer in the presence of acid or base according to methods known to those skilled in the art or as described in the accompanying examples.

[0048] During any of the above synthetic sequences it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by conventional protecting groups such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973, and T.W. Greene & P. ​​G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd edition, 1999. The protecting groups may be removed at any convenient subsequent stage using methods well known in the art.

[0049] The compounds of formula (I) according to the present invention do not directly activate the dopamine D1 receptor, but potentiate the effect of D1 agonists or endogenous ligands on the D1 receptor, dopamine, via an allosteric mechanism and are therefore D1 positive allosteric modulators (D1 PAMs).

[0050] Dopamine and other D1 agonists themselves directly activate the dopamine D1 receptor. The assays are designed to measure the effects of compounds according to the invention in the absence of dopamine (the "activation assay") and in the presence of dopamine (the "potentiation assay"). The activation assay measures stimulation of cyclic adenosine monophosphate (cAMP) production in a homogeneous time-resolved fluorescence (HTRF) assay, with 100% activation defined as the maximal increase in cAMP with increasing concentrations of the endogenous agonist, dopamine. In tests, compounds of formula (I) according to the invention lack a significant direct agonist-like effect, since when present at a concentration of 10 μM, the extent of activation is less than 20% (relative to the maximum dopamine response).

[0051] The potentiation assay measures the ability of a compound to increase the level of cAMP produced by a low-threshold concentration of dopamine. The concentration of dopamine used (EC20) is designed to produce a 20% stimulation compared to the maximal response (100%) seen with increasing concentrations of dopamine. To measure this potentiation, increasing concentrations of a compound with the EC20 of dopamine are incubated, and potentiation is measured as an increase in cAMP production. The concentration of compound that produces 50% potentiation of cAMP levels is determined.

[0052] When tested in the cAMP HTRF assay, the compound of formula (I) according to the present invention exhibits a pEC50 value of greater than about 7.5, indicating that it is a D1 positive allosteric modulator. GABA A Receptor inhibition is known to be closely related to seizures and epilepsy, therefore it is desirable to develop compounds that are D1 positive allosteric modulators while at the same time minimizing such effects. Thus, when tested in the GABA-A receptor inhibition assay described herein, the compounds of formula (I) inhibited less than about 5% of the GABA A receptor activity when measured at a concentration of 10 μM of the compound of formula (I). A It is desirable to show the percentage of receptor inhibition.

[0053] cAMP HTRF assay The conditions for testing the compounds of the present invention are specifically described below. a. Method D1 cell culture Cells were cultured at 37°C in a humidified atmosphere of 5% CO. Cells were grown in DMEM-F12 + GlutaMAX™-I medium (GIBCO®, Invitrogen, Merelbeke, Belgium) containing 10% fetal bovine serum (BioWhittaker®, Lonza, Verviers, Belgium), 400 μg / mL Geneticin (GIBCO®), 100 IU / mL penicillin, and 100 IU / mL streptomycin (Pen-Strep solution, BioWhittaker®). LMtk (Ltk-) mouse fibroblasts expressing dopamine D1 receptors (BioSignal Inc, Montreal, Canada, now Perkin Elmer) were used because they have been shown to efficiently bind and confer robust functional responses (Watts et al., 1995).

[0054] b. cAMP assay Measurement of changes in intracellular cyclic adenosine monophosphate (cAMP) was determined using the HTRF cAMP kinetic assay kit from CisBio (Codres, France). Using homogeneous time-resolved fluorescence technology, the assay is based on the competition between natural cAMP produced by the cells and cAMP labeled with the dye d2. Tracer binding is determined by an anti-cAMP antibody labeled with cryptate. The effect of the compound alone (agonism) was determined by performing the assay in the absence of dopamine, while the effect of the compound as a positive allosteric modulator (PAM) was determined by measuring the EC 20 Cells (20,000 cells per well) were incubated with isobutylmethylxanthine (Sigma, final 0.1 mM), various concentrations of test compound (typically 10%), and 100% ATP in the presence or absence of dopamine (final 1.1 nM). -9.5 M~10 -4.5The cells are incubated in a 384-well plate for 1 hour at room temperature in a final volume of 20 μL of HBSS (Lonza, containing calcium, magnesium, and HEPES buffer 20 mM, pH 7.4) containing 10 mM of d2. The reaction is then terminated and the cells are lysed by adding d2 detection reagent in lysis buffer (10 μL) and cryptate reagent in lysis buffer (10 μL) according to the manufacturer's instructions. This is then incubated for a further 60 minutes at room temperature, and the change in the HTRF fluorescence emission ratio is determined using an Envision plate reader with laser excitation (Perkin Elmer, Zaventem, Belgium) according to the manufacturer's instructions. All incubations were performed in duplicate, and the results were compared to a concentration-effect curve for dopamine (10 μL). -11 M~10 -6 M).

[0055] c. Data analysis Data were analyzed using Excel and PRISM (GraphPad Software) to calculate pEC using a four-parameter logistic equation (DeLean et al., 1978). 50 and Erel was obtained, where Erel is the matched maximal response of the test compound minus the basal value, expressed as a percentage of that obtained with dopamine, which was defined as 100%.

[0056] pEC of the compound 50 is the −log10 of the concentration of compound that produces 50% of the enhancement of cAMP levels. Erel is the relative efficacy measured, defined as the % maximal enhancement produced by a compound compared to the maximal response produced by increasing concentrations of dopamine (Erel 1 = maximal dopamine response). When tested in the above assay, the compound of formula (I) exhibits a pEC50 value of about 8.2 and an Erel value of about 62%.

[0057] GABA A Automated patch clamp studies on receptor cells Human GABAA CHO-K1 cells stably expressing the receptor α1, β2, and γ2 subunits were used. Cells were harvested using trypsin and maintained in serum-free medium at room temperature. Cells were washed and resuspended in extracellular solution before testing.

[0058] Patch clamp testing Human GABA A Experiments on α1β2γ2 channels were performed using an automated patch clamp assay (IonFlux™ HT). Compounds were tested at three concentrations (0.1, 1, and 10 μM) in triplicate cells. GABA A The external solution for recording currents consisted of 137 mM sodium chloride, 4 mM potassium chloride, 1.8 mM calcium chloride, 1 mM magnesium chloride, 10 mM HEPES, and 10 mM glucose. Both the external and internal solutions were titrated with NaOH or KOH to obtain a pH of 7.35 or 7.3, respectively. The internal pipette solution contained 70 mM potassium fluoride, 60 mM potassium chloride, 70 mM sodium chloride, 5 mM HEPES, 5 mM EGTA, and 4 mM magnesium ATP. The final concentration of vehicle used to dilute compounds was 0.33% DMSO in each well. Bicuculline (0.032–100 μM) was used as a positive control inhibitor. GABA (15 μM) was used as an agonist. All recordings were obtained from a holding potential of -60 mV.

[0059] The order of compound addition was as follows: EC 80 A single addition of 15 μM GABA was used to establish a baseline response. Each compound concentration was applied for 30 seconds, followed by a 2-second addition of 15 μM GABA in the presence of compound. The procedure was repeated with the next increasing concentration of compound. The peak inward current in response to the addition of GABA in the presence of a single compound concentration was measured. All compound data were normalized to the baseline peak current induced by the 2-second addition of 15 μM GABA.

[0060] When tested in the above assay, at a concentration of 10 μM, the compounds of formula (I) exhibited less than about 0.1% of the GABA receptor activity measured at a concentration of 10 μM of the compound of formula (I). A The percentage of receptor inhibition is shown.

[0061] The following examples illustrate the preparation of compounds of formula (I) according to the invention. example Abbreviations / Repeated Reagents ACN: acetonitrile Brine: saturated aqueous sodium chloride solution nBu: n-butyl tBu: tert-butyl COMU:(1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate DCM: dichloromethane DMAP: 4-dimethylaminopyridine DMF: N,N-dimethylformamide DMSO: dimethyl sulfoxide EC 20 / 50 : Concentration that produces 20% / 50% of the maximum response Erel: Relative Effectiveness ES + : Electrospray positive ionization Et: Ethyl EtOH: ethanol Et2O: Diethyl ether EtOAc: ethyl acetate h: time HPLC: High-pressure liquid chromatography HTRF: Homogeneous time-resolved fluorescence LCMS: Liquid Chromatography Mass Spectrometry MeOH: Methanol min.:minutes NCS: N-chlorosuccinimide NMR: nuclear magnetic resonance iPrOH: Isopropanol rt: room temperature SFC: Supercritical Fluid Chromatography TEA: Triethylamine THF: tetrahydrofuran TLC: Thin Layer Chromatography cAMP: cyclic adenosine monophosphate IUPAC names were generated using either Biovia Draw version 19.1 (2019) or 20.1 (2020).

[0062] Analysis method All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen or argon atmosphere using dry solvents and glassware. Commercially available solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate (generally Sure-Seal™ products from Aldrich Chemical Company or AcroSeal™ from ACROS Organics). In general, reactions were followed by thin-layer chromatography, HPLC, or mass spectrometry.

[0063] Mass spectrometry measurements in LCMS mode are performed using different methods and instruments as follows: -Basic LCMS method 1: A QDA Waters simple quadrupole mass spectrometer is used for LCMS analysis. The spectrometer is equipped with a UPLC Acquity Classic equipped with an ESI source and a diode array detector (210-400 nm). Data are acquired as full MS scans from m / z 70-800 in positive / negative mode using basic elution. Reversed-phase separation is performed on a Waters Acquity UPLC BEH C18 1.7 μm (2.1 × 50 mm) column at 45 °C for basic elution. Gradient elution is performed using HO / ACN / ammonium formate (95 / 5 / 63 mg / L) + 100 μL / L NH4OH (solvent A) and ACN / HO / ammonium formate (95 / 5 / 63 mg / L) + 100 μL / L NH4OH (solvent B). Injection volume: 1 μL. Total flow rate on MS. [Table 1]

[0064] -Acidic LCMS method 1: A QDA Waters simple quadrupole mass spectrometer is used for LCMS analysis. The spectrometer is equipped with a UPLC Acquity with an ESI source and a diode array detector (200-400 nm). Data are acquired as full MS scans from m / z 70 to 800 in positive / negative mode using acidic elution. Reversed-phase separation is performed on a Waters Acquity UPLC HSS T3 1.8 μm (2.1 × 50 mm) column at 45 °C for acidic elution. Gradient elution is performed using HO / ACN / TFA (95 / 5 / 0.05%) (solvent A) and ACN (solvent B). [Table 2]

[0065] Some reaction mixtures could be processed using Isolute® separator phase cartridges (Biotage), acidic columns or capture and release SPE (solid phase extraction) cartridges. Crude materials could be purified by normal phase chromatography, preparative TLC, (acidic or basic) reverse phase chromatography, chiral separation, tritylation or recrystallization.

[0066] Normal phase chromatography was performed using a silica gel column (100:200 mesh silica gel or a cartridge for a normal phase column chromatography system, such as Biotage® Isolera™ Four or Teledyne Isco CombiNormal phase column®). Products were generally dried under vacuum before final analysis and biological testing.

[0067] NMR spectra were recorded on a Windows 7 Professional workstation running Topspin 3.2 software and a 5 mm double-resonance broadband probe (PABBI 1 H / 19 F-BB Z-GRD Z82021 / 0075 or 1mm triple resonance probe (PATXI 1 H / D- 13 C / 15 The NMR spectra were recorded on a BRUKER AVANCE III 400 MHz-Ultrashield NMR spectrometer equipped with a 1000 MHz NMR spectrometer (N Z-GRD Z868301 / 004).

[0068] Chemical shifts are referenced to signals from residual protons of the deuterated solvent (DMSO-d6, MeOH-d4, or CDCl3). Chemical shifts are given in parts per million (ppm), and coupling constants (J) are given in Hertz (Hz). Spin multiplicities are given as broad (br), singlet (s), doublet (d), triplet (t), quartet (q), and multiplet (m). All final products were analyzed by LCMS in both basic and acidic modes as follows:

[0069] -Basic LCMS method 2: A QDA Waters simple quadrupole mass spectrometer was used for LCMS analysis. The spectrometer was equipped with a UPLC Acquity Classic equipped with an ESI source and a diode array detector (210-400 nm). Data were acquired as full MS scans from m / z 70 to 800 in positive / negative mode using basic elution. Reversed-phase separation was performed on a Waters Acquity UPLC BEH C18 1.7 μm (2.1 × 100 mm) column at 45 °C for basic elution. Gradient elution was performed using HO / ACN / ammonium formate (95 / 5 / 63 mg / L) + 100 μL / L NH4OH (solvent A) and ACN / HO / ammonium formate (95 / 5 / 63 mg / L) + 100 μL / L NH4OH (solvent B). Injection volume: 1 μL. Total flow rate on MS. [Table 3]

[0070] -Acidic LCMS method 2: A QDA Waters simple quadrupole mass spectrometer is used for LCMS analysis. The spectrometer is equipped with a UPLC Acquity Hclass with an ESI source and a diode array detector (210-400 nm). Data are acquired as full MS scans from m / z 70 to 800 in positive / negative mode using acidic elution. Reversed-phase separation is performed on a Waters Acquity UPLC HSS T3 1.8 μm (2.1 × 100 mm) column at 45 °C for acidic elution. Gradient elution is performed using HO / ACN / TFA (95 / 5 / 0.05%) (solvent A) and ACN (solvent B). [Table 4]

[0071] 1. Preparation of intermediate of formula (II) - 2-(3,5-dichloro-1H-indazol-4-yl)acetic acid [ka] To a solution of 2-(5-chloro-1H-indazol-4-yl)acetic acid X (CAS: 1904662-08-3, WO2016055479, 2.1 g, 10 mmol) in DMF (10 mL) was added NCS (1.5 g, 11 mmol) portionwise at room temperature, and the mixture was stirred overnight. The reaction mixture was quenched by adding 100 mL of water dropwise. After stirring for 1 hour, the product precipitated. The solid was filtered and washed twice with the mother liquor and twice with water (50 mL). The solid was then dried overnight under vacuum at 45 °C to give 2-(3,5-dichloro-1H-indazol-4-yl)acetic acid (2.0 g, 7.62 mmol, 93% purity, 76% yield), which was used in the next step without further purification.

[0072] Acidic LCMS method 2 (ES + ):245 / 247 / 249(M+H) + 1 H NMR (400 MHz, DMSO-d6): δ 13.52 (s, 1H), 7.52 (d, J = 8.9 Hz, 1H), 7.47 (d, J = 8.9 Hz, 1H), 4.21 (s, 2H)

[0073] 2. Preparation of Compounds of Formula (I) 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone [ka]

[0074] 2.1. Preparation of intermediate (IX) (2R)2-amino-3-(2-bromophenyl)propan-1-ol -a6 (2R)2-Amino-3-(2-bromophenyl)propanoic acid a5 (34.0 kg, 139 mol) and THF (238 L) were charged to a reactor. Sodium borohydride (15.6 kg, 413 mol) was added slowly at 20-30°C. A solution of iodine (35.3 kg, 139 mol) in dry THF (20.0 L) was added slowly at 0-10°C, and the reaction mixture was stirred at 70°C for 12 h. The reaction was quenched with methanol (70.0 L) at 0°C and heated to 80°C for 30 min. The mixture was cooled and concentrated under vacuum, and the residue was suspended in NaOH (30.0 L, 2N) and then filtered. The filter cake is dried under vacuum to give (2R)-2-amino-3-(2-bromophenyl)propan-1-ol a6 as a white solid (31.0 kg, 135 mol, 96.7% yield), which is used in the next step without further purification.

[0075] 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 7.7 Hz, 1H), 7.21 - 7.29 (m, 2H), 7.07 - 7.15 (m, 1H), 3.66 (dd, J = 10.5, 3.6 Hz, 1H), 3.41 (dd, J = 10.5, 7.2 Hz, 1H), 3.18 - 3.29 (m, 1H), 2.95 (dd, J = 13.5, 5.5 Hz, 1H), 2.70 (dd, J = 13.5, 8.2 Hz, 1H), 1.51 - 1.91 (m, 3H).

[0076] 2.2. Preparation of intermediates of formula (VIII) (4R)-4-[(2-bromophenyl)methyl]oxazolidin-2-one-a7 (2R)-2-amino-3-(2-bromophenyl)propan-1-ol a6 (31.0 kg, 135 mol) and dichloromethane (220 L) are charged to a reactor. Triphosgene (13.9 kg, 47.1 mol) is added at room temperature, followed by the slow addition of N,N-diisopropylethylamine (39.1 kg, 303 mol) at 0-10°C. The reaction mixture is stirred at 0-10°C for 1 hour, then washed twice with water (50.0 L), dried over anhydrous sodium sulfate, and filtered to give (4R)-4-[(2-bromophenyl)methyl]oxazolidin-2-one a7 as a solution in dichloromethane, which is used directly in the next step.

[0077] 2.3. Preparation of intermediate (VII) (10aR)-9-Bromo-1,5,10,10a-tetrahydrooxazolo[3,4-b]isoquinolin-3-one a8 A solution of (4R)-4-[(2-bromophenyl)methyl]oxazolidin-2-one a7 (135 mol) in dichloromethane (220 L) was charged to a reactor and cooled to 0-5°C. Trimethylsilyl triflate (35.9 kg, 162 mol) and paraformaldehyde (13.3 kg, 148 mol) were added at 0-5°C, followed by stirring at 15-20°C for 2 hours. Water (170 L) was added to the mixture, which was then extracted twice with dichloromethane (50.0 L). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. A mixture of petroleum ether:ethyl acetate (1:1, 45.0 L) was added, and the mixture was stirred at room temperature for 6 hours and filtered. The solid was dried to give (10aR)-9-bromo-1,5,10,10a-tetrahydrooxazolo[3,4-b]isoquinolin-3-one a8 as an off-white solid (29.0 kg, 80.2% yield).

[0078] 1 H NMR (400 MHz, CDCl3) δ 7.45 - 7.52 (m, 1H), 7.08 - 7.14 (m, 2H), 4.83 (d, J = 17.0 Hz, 1H), 4.62 (t, J = 8.4 Hz, 1H), 4.36 (d, J = 17.0 Hz, 1H), 4.21 (dd, J = 8.6, 4.9 Hz, 1H), 3.91 - 3.99 (m, 1H), 3.25 (dd, J = 16.3, 4.2 Hz, 1H), 2.67 (dd, J = 16.1, 11.0 Hz, 1H).

[0079] 2.4. Preparation of intermediate (VI) 2.4.1. [(3R)-5-Bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol a9 Ethanol (120 L) and water (60.0 L) were mixed in a reactor. (10aR)-9-bromo-1,5,10,10a-tetrahydrooxazolo[3,4-b]isoquinolin-3-one a8 (29.7 kg, 111 mol) was added, followed by the slow addition of sodium hydroxide (13.3 kg, 332 mol) at 15-20 °C. The reaction mixture was stirred at 90 °C for 2 hours and then cooled to room temperature. Water (300 L) was added to the mixture, which was then centrifuged. The centrifuge cake was dried in a circulating oven to obtain [(3R)-5-bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol a9 as a white solid (23.7 kg, 88.3% yield), which was used in the next step without further purification.

[0080] 1 H NMR (400 MHz, CDCl3) δ 7.37 - 7.47 (m, 1H), 6.95 - 7.08 (m, 2H), 4.00 - 4.10 (m, 2H), 3.85 (dd, J = 10.9, 3.7 Hz, 1H), 3.57 (dd, J = 10.9, 7.9 Hz, 1H), 3.06 (ddt, J = 11.3, 7.6, 4.1, 4.1 Hz, 1H), 2.79 (dd, J = 17.1, 4.4 Hz, 1H), 2.40 (dd, J = 17.1, 10.9 Hz, 1H), 1.93 (br s, 2H).

[0081] 2.4.2. [(3R)-5-Bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane a10 [(3R)-5-Bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol a9 (23.7 kg, 97.8 mol) and dichloromethane (240 L) were charged to a reactor. DMAP (120 g, 0.98 mol) and imidazole (13.3 kg, 196 mol) were added. tert-Butyldimethylsilyl chloride (TBSCl) (17.7 kg, 117 mol) was added slowly at 15-20 °C, and the mixture was stirred for 12 h. Ammonium chloride (100 L) was added to the mixture. The organic phase is separated, washed with water (50.0 L), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give [(3R)-5-bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane a10 as a yellow oil (37.6 kg, 86% purity, 93% yield), which is used in the next step without further purification.

[0082] 1 H NMR (400 MHz, CDCl3) δ 7.36 - 7.45 (m, 1H), 7.01 (d, J = 4.6 Hz, 1H), 4.01 - 4.13 (m, 2H), 3.84 (dd, J = 9.9, 3.7 Hz, 1H), 3.64 (dd, J = 9.8, 7.2 Hz, 1H), 2.96 - 3.08 (m, 1H), 2.75 (dd, J = 17.0, 4.2 Hz, 1H), 2.44 (dd, J = 17.0, 10.8 Hz, 1H), 1.76 - 2.20 (m, 2H), 0.89 - 0.97 (m, 9H), 0.08 - 0.14 (m, 6H).

[0083] 2.5. Preparation of Intermediate (V) [(3R)-5-Bromo-3,4-dihydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane a11 [(3R)-5-Bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane a10 (3.42 kg, 8.31 mol) and THF (30.0 L) are charged to a reactor. N-Chlorosuccinimide (NCS) (1.17 kg, 8.73 mol) is added slowly at room temperature, and the mixture is stirred at 25°C for 30 minutes. A solution of KOH (1.52 kg, 27.1 mol) in dry methanol (7.00 L) is added slowly at room temperature, and the reaction is stirred at 25°C for 1 hour. The reaction is quenched with water (10.0 L) and extracted with petroleum ether:ethyl acetate (1:2, 5.00 L). The organic layer is separated, washed with brine (10.0 L), dried over anhydrous sodium sulfate, and filtered. This overall procedure was carried out in parallel on 10 batches of equal size, and the 10 reaction filtrates were combined and concentrated under vacuum to give [(3R)-5-bromo-3,4-dihydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane a11 as a brown oil (28.0 kg, crude), which was used in the next step without further purification.

[0084] 1 H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 2.6 Hz, 1H), 7.58 (dd, J = 7.8, 1.2 Hz, 1H), 7.12 - 7.25 (m, 2H), 4.03 (dd, J = 9.5, 4.0 Hz, 1H), 3.67 - 3.77 (m, 2H), 3.07 (dd, J = 17.0, 6.2 Hz, 1H), 2.68 (dd, J = 17.1, 10.9 Hz, 1H), 0.88 - 0.91 (m, 9H), 0.07 (d, J = 1.5 Hz, 6H).

[0085] 2.6. Preparation of intermediates of formula (IV) 2.6.1. [(1S,3R)-5-Bromo-1-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane (IVa) [(3R)-5-Bromo-3,4-dihydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane a11 (3.10 kg, 8.75 mol) and THF (20.0 L) are charged to a reactor. The mixture is cooled to 0 °C, and methylmagnesium chloride (3 M, 11.6 L) is added. The mixture is stirred at 20 °C for 12 hours. The reaction is quenched with a saturated solution of ammonium chloride. The phases are separated, and the aqueous layer is extracted twice with petroleum ether:ethyl acetate (3:1, 5.00 L). The combined organic phases are washed with brine (10.0 L), dried over anhydrous sodium sulfate, and filtered. This overall procedure is carried out in parallel on nine batches of the same size, and the nine reaction filtrates are combined and concentrated under vacuum. The crude mixture was purified by silica gel chromatography using petroleum ether:ethyl acetate (10:1) to give [(1S,3R)-5-bromo-1-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane (IVa) as a brown oil (4.60 kg, purity 99.7%, yield 15.7%).

[0086] 1 H NMR (400 MHz, DMSO-d6) δ 7.41 (dd, J=7.7, 0.9 Hz, 1H), 7.12 - 7.18 (m, 1H), 7.03 - 7.11 (m, 1H), 4.12 (q, J=6.8 Hz, 1H), 3.62 (d, J=5.7 Hz, 2H), 3.07 - 3.17 (m, 1H), 2.67 - 2.76 (m, 1H), 2.26 (dd, J=16.9, 10.0 Hz, 1H), 2.12 (br s, 1H), 1.32 (d, J=6.8 Hz, 3H), 0.84 - 0.93 (m, 9H), 0.07 (d, J=0.9 Hz, 6H).

[0087] 2.6.2. tert-Butyl (1S,3R)-5-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (IVb) [(1S,3R)-5-Bromo-1-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane (IVa) (1.85 kg, 4.99 mol) and dichloromethane (13.0 L) are charged to a reactor. N,N-Diisopropylethylamine (1.94 kg, 14.9 mol) and di-tert-butyl dicarbonate (1.14 kg, 5.24 mol) are added at room temperature, and the mixture is stirred for 12 hours. The reaction mixture is washed twice with saturated ammonium chloride solution (10.0 L), and the organic layer is dried over anhydrous sodium sulfate and filtered. This entire procedure is carried out in parallel on two batches of the same size. The two reaction filtrates are combined and concentrated under vacuum. The crude mixture is purified by silica gel chromatography using petroleum ether:ethyl acetate (30:1) to give tert-butyl (1S,3R)-5-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (IVb) as a yellow oil (4.00 kg, 99.5% purity, 85.2% yield).

[0088] 1 H NMR (400 MHz, DMSO-d6) δ 7.50 (d, J = 7.9 Hz, 1H), 7.22 (br d, J = 6.7 Hz, 1H), 7.06 - 7.18 (m, 1H), 4.84 (br s, 1H), 4.12 (br s, 1H), 3.46 (br d, J = 15.4 Hz, 2H), 2.94 (br dd, J = 15.8, 5.2 Hz, 1H), 2.71 (br t, J = 9.5 Hz, 1H), 1.45 (s, 9 H), 1.28 (br s, 3H), 0.81 (s, 9H), -0.08 (s, 6H).

[0089] 2.6.3. tert-Butyl (1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (IVc) A solution of tert-butyl (1S,3R)-5-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (IVb) (42.5 g, 90.3 mmol) in dry THF (0.5 M solution) and a commercially available solution of n-butyllithium in hexane (1.6 M solution) were pumped at 6.0 mL / min (1.0 equivalent) and 2.46 mL / min (1.3 equivalent), respectively, and mixed in a glass microchip cooled to -40 °C. The combined flow stream was pumped through reaction zone 1 of the microchip (0.3 mL) and then combined with a solution of dry acetone (13.5 M) pumped at 6.0 mL / min (27 equivalents). The resulting stream was then passed through reaction zone 2 of the microchip (0.7 mL) at -40 °C. Finally, the overall flow stream exiting the reactor was collected and quenched at room temperature in a saturated solution of aqueous ammonium chloride. The entire feed solution was consumed, yielding a biphasic reaction mixture. The aqueous layer was separated from the organic layer and then extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. A yellow oil (46.5 g) was obtained and purified by SFC chromatography on a GreenSep Nitro column (10 μm, 5×22.3 ml, eluting with 98% CO2 / 2% EtOH). The solvent was removed under vacuum to yield a white solid, tert-butyl (1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (IVc) (25 g, 56 mmol, 62% yield).

[0090] UPLC_MS basic: 1 peak at 3.83 min (ES+): 350 (M-Boc+H) + , 332 (M-Boc-H2O+H) + , 100% purity. 1H NMR (400 MHz, DMSO-d6) δ 7.44 (d, J = 7.9 Hz, 1H), 7.19 (dt, J = 8.1, 5.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 4.99 (s, 1H), 4.87 (dq, J = 13.4, 6.4 Hz, 1H), 4.11 (s, 1H), 3.96 (t, J = 14.9 Hz, 1H), 3.48 (dd, J = 9.4, 4.1 Hz, 1H), 2.98 (dd, J = 16.5, 5.0 Hz, 1H), 2.89 (t, J = 9.6 Hz, 1H), 1.65 (s, 3H), 1.58 (s, 3H), 1.55 (d, J = 2.5 Hz, 9H), 1.34 (dd, J = 20.5, 6.6 Hz, 3H), 0.90 (s, 9H), 0.08 (d, J = 7.2 Hz, 3H), -0.00 (s, 3H).

[0091] 2.7. Preparation of intermediate (III) tert-butyl-dimethyl-[[(1S,3R)-1-methyl-5-(1-methyl-1-trimethylsilyloxy-ethyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy]silane tert-Butyl (1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (IVc) (148 g, 87% purity, 287 mmol) was dissolved in 1000 mL of dichloromethane and transferred to a 2-L double-walled reactor. 2,6-Lutidine (100 mL, 860 mmol) was added and the jacket temperature was set to -2 °C. Trimethylsilyl trifluoromethanesulfonate (154 g, 129 mL, 692 mmol) was added via an addition funnel over 40 min. Two hours after the start of the addition, the reaction was quenched by the addition of 650 mL of aqueous citric acid (1 M), and the mixture was allowed to return to a temperature of 20 °C. One hour after the start of the quench, the layers were separated. The organic layer is washed twice with 350 mL of aqueous citric acid (1 M). The organic layer is stirred with 750 mL of aqueous sodium carbonate (10% w / w) for 10 minutes, and then the layers are separated. The organic layer is dried over anhydrous sodium sulfate. The organic layer is then filtered, and the filtrate is concentrated under vacuum at 40° C. to give tert-butyl-dimethyl-[[(1S,3R)-1-methyl-5-(1-methyl-1-trimethylsilyloxy-ethyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy]silane (III) as a yellow oil (128 g), which is used in the next step without further purification.

[0092] 1H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 7.7 Hz, 1H), 7.07 (t, J = 7.7 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 4.24 (q, J = 6.8 Hz, 1H), 3.75 (dd, J = 9.7, 4.4 Hz, 1H), 3.60 (dd, J = 9.7, 7.0 Hz, 1H), 3.54 (dd, J = 16.3, 3.5 Hz, 1H), 3.15 (ddt, J = 10.9, 7.4, 4.0 Hz, 1H), 2.52 (dd, J = 16.3, 10.9Hz, 1H), 1.66 (d, J = 14.6 Hz, 6H), 1.52 - 1.43 (m, 3H), 0.92 (q, J = 1.2 Hz, 9H), 0.14 (q, J = 1.2 Hz, 2H), 0.09 (d, J = 1.1 Hz, 6H), 0.00 (q, J = 1.2, 0.8 Hz, 9H).

[0093] 2.8. Preparation of Compound of Formula (I) 2-(3,5-Dichloro-1H-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone To a solution of 2-(3,5-dichloro-1H-indazol-4-yl)acetic acid (II) (200 mg, 0.82 mmol) in DMF (2.00 mL) at room temperature was added tert-butyl-dimethyl-[[(1S,3R)-1-methyl-5-(1-methyl-1-trimethylsilyloxy-ethyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy]silane (413 mg, 0.98 mmol), DIPEA (405 μL, 2.44 mmol), and COMU (398 mg, 0.90 mmol). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EtOAc and water, the layers were separated, and the aqueous layer was extracted with EtOAc (3 times). The combined organic layers were washed with water (3 times), saturated aqueous NaHCO3, brine, dried over Na2SO4, filtered, and concentrated to give a brown residue. The crude product was filtered through silica (25 g SFAR silica gel column with a gradient of heptane: EtOAc 100:0 to 0:100) to afford 1-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-methyl-5-(1-methyl-1-trimethylsilyloxy-ethyl)-3,4-dihydro-1H-isoquinolin-2-yl]-2-(3,5-dichloro-1H-indazol-4-yl)ethanone and 1-[(1S,3R)-3-[[tert-butyl(di A (1:1) mixture of [methyl]silyl]oxymethyl]-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(3,5-dichloro-1H-indazol-4-yl)ethanone (320 mg) was obtained as a yellow oil, which was directly dissolved in THF (3 mL) at room temperature, followed by the addition of TBAF (1.02 mL, 1.02 mmol). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EtOAc and water, the layers were separated, and the organic layer was washed with water (3 times), dried over Na2SO4, filtered, and concentrated to give a colorless oil. The crude product was purified by HPLC under basic conditions (20% to 100% CH3CN in water / NH4OH).

[0094] Purification by reverse-phase flash chromatography Biotage Isolera Four on a SNAP 60 g gel column (1.0 g portions) afforded 2-(3,5-dichloro-1H-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone (I) (37.0 mg, 0.08 mmol, 10% yield) as a white solid.

[0095] Basic LCMS Method 2: 1 peak at 3.72 min (ES + ):462[M+H] + , purity 98%. Acidic LCMS Method 2: 1 peak at 4.14 min (ES + ):462[M+H] + , 98% purity. 1 H NMR (400 MHz, DMSO-d6) δ 7.54 - 7.49 (m, 1H), 7.49 - 7.43 (m, 1H), 7.40 (dd, J = 7.5, 1.8 Hz, 0.3H), 7.35 (dd, J = 7.9, 1.3 Hz, 0.7H), 7.23 - 7.04 (m, 2H), 5.31 (q, J = 6.6 Hz, 0.3H), 5.14 (s, 0.3H), 5.12 (s, 0.7H), 5.05 (q, J = 6.4 Hz, 0.7H), 4.96 (t, J = 5.5 Hz, 0.7H), 4.64 - 4.30 (m, 3H), 4.17 (q, J = 5.4 Hz, 0.3H), 4.10 -3.98 (m, 1H), 3.30 (tt, J = 9.8, 5.0 Hz, 1H), 3.05 (dd, J = 16.1, 4.4 Hz, 1H), 2.97 (p, J = 7.8, 6.3 Hz, 1H), 1.57 (d, J = 9.6 Hz, 6H), 1.53 (s, 1H), 1.24 (d, J = 6.5 Hz, 2H).

Claims

1. 2-(3,5-Dichloro-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone of formula (I) or a pharmaceutically acceptable salt thereof. 【Chemistry 1】

2. 10. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof for use in therapy.

3. 10. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment and / or prevention of diseases and / or disorders in which the D1 receptor is involved.

4. 10. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 for use in the treatment and / or prevention of cognitive and negative symptoms in schizophrenia, cognitive impairment associated with neuroleptic therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinsonism-related dementia, Huntington's disease, dementia with Lewy bodies, Alzheimer's disease, drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain.

5. 10. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of cognitive and negative symptoms in Parkinson's disease and other movement disorders, Alzheimer's disease, or schizophrenia.

6. 10. Use of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament useful for the treatment and / or prevention of diseases and / or disorders in which the D1 receptor is involved.

7. 10. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 for the manufacture of a medicament useful for the treatment and / or prevention of cognitive and negative symptoms in schizophrenia, cognitive impairment associated with neuroleptic therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinsonism-related dementia, Huntington's disease, dementia with Lewy bodies, Alzheimer's disease, drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain.

8. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

Images